Jeevan Scientific Technology Limited
BSE: JSTL · Healthcare Research, Analytics & Technology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Jeevan Scientific Technology Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Jeevan Scientific Technology Limited is a Hyderabad-based contract research organisation providing clinical trial, bioanalytical, and pharmacovigilance services to the pharmaceutical industry. The company also offers specialized healthcare software solutions and staffing services to support drug development and post-marketing surveillance.
Business Model
The company operates as a service provider for the pharmaceutical and biopharmaceutical sectors, generating revenue through clinical research contracts and the provision of healthcare-focused IT software and staffing solutions.
Growth Outlook
Growth is driven by the increasing demand for outsourced clinical research services and the integration of specialized technology solutions within the global drug development lifecycle.
Key Risks
- Regulatory Compliance. Failure to adhere to stringent international clinical trial standards could lead to loss of accreditation and legal repercussions.
- Client Concentration. Reliance on a limited number of pharmaceutical clients may lead to significant revenue volatility if key contracts are terminated.
- Data Security. As a provider of healthcare IT and data management, the company faces risks related to the protection of sensitive patient and clinical trial data.
- Sector Competition. The contract research organisation market is highly competitive, potentially pressuring margins and service pricing.
Start your research today
Unlock AI insights, financials, peers and live data on Jeevan Scientific Technology Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹62 Cr
TTM · consolidated
NET PROFIT
₹7 Cr
TTM · consolidated
EPS
₹4.48
TTM · consolidated
RETURN ON EQUITY
13.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
16.2%
TTM · consolidated
P/E
18.9x
Q4 FY26 · consolidated
EV/EBITDA
8.9x
Q4 FY26 · consolidated
EBITDA MARGIN
29.7%
TTM · consolidated
NET PROFIT MARGIN
8.6%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Jeevan Scientific Technology LimitedJSTL | ₹155 Cr | 18.91 | 8.89 | 31.4% | 29.7% | 13.5% | 16.2% | +138.7% |
Indegene Ltd.INDGN | ₹14,419 Cr | 35.52 | 19.70 | 30.4% | 18.8% | 13.9% | 17.4% | +4.9% |
Suven Life Sciences LimitedSUVEN | ₹9,659 Cr | -20.71 | -27.94 | 17.3% | -557.4% | -100.5% | -99.8% | +48.9% |
Vimta LabsVIMTALABS | ₹2,728 Cr | 32.72 | 17.34 | 15.2% | 37.3% | 19.1% | 24.1% | -18.3% |
Fabtech Technologies LimitedFABTECH | ₹661 Cr | 10.28 | 9.04 | — | 16.3% | 11.6% | 14.1% | — |
Take SolutionsTAKE | ₹235 Cr | 14.71 | 37.62 | — | 7.4% | 49.8% | 24.2% | +4.9% |
As of Q4 FY26
Financials
Jeevan Scientific Technology Limited
BSE: JSTL · Healthcare Research, Analytics & Technology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Jeevan Scientific Technology Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Jeevan Scientific Technology Limited is a Hyderabad-based contract research organisation providing clinical trial, bioanalytical, and pharmacovigilance services to the pharmaceutical industry. The company also offers specialized healthcare software solutions and staffing services to support drug development and post-marketing surveillance.
Business Model
The company operates as a service provider for the pharmaceutical and biopharmaceutical sectors, generating revenue through clinical research contracts and the provision of healthcare-focused IT software and staffing solutions.
Growth Outlook
Growth is driven by the increasing demand for outsourced clinical research services and the integration of specialized technology solutions within the global drug development lifecycle.
Key Risks
- Regulatory Compliance. Failure to adhere to stringent international clinical trial standards could lead to loss of accreditation and legal repercussions.
- Client Concentration. Reliance on a limited number of pharmaceutical clients may lead to significant revenue volatility if key contracts are terminated.
- Data Security. As a provider of healthcare IT and data management, the company faces risks related to the protection of sensitive patient and clinical trial data.
- Sector Competition. The contract research organisation market is highly competitive, potentially pressuring margins and service pricing.
Start your research today
Unlock AI insights, financials, peers and live data on Jeevan Scientific Technology Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹62 Cr
TTM · consolidated
NET PROFIT
₹7 Cr
TTM · consolidated
EPS
₹4.48
TTM · consolidated
RETURN ON EQUITY
13.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
16.2%
TTM · consolidated
P/E
18.9x
Q4 FY26 · consolidated
EV/EBITDA
8.9x
Q4 FY26 · consolidated
EBITDA MARGIN
29.7%
TTM · consolidated
NET PROFIT MARGIN
8.6%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Healthcare Research, Analytics & Technology
As of Q4 FY26